Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Don P Wilson; Terry A Jacobson; Peter H Jones; Marlys L Koschinsky; Catherine J McNeal; Børge G Nordestgaard; Carl E Orringer

doi:10.1016/j.jacl.2019.04.010

Back

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Journal article

Peer reviewed

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Don P Wilson, Terry A Jacobson, Peter H Jones, Marlys L Koschinsky, Catherine J McNeal, Børge G Nordestgaard and Carl E Orringer

Journal of clinical lipidology, Vol.13(3), pp.374-392

2019-05

DOI: https://doi.org/10.1016/j.jacl.2019.04.010

PMID: 31147269

Abstract

Blood Chemical Analysis

Humans

Societies, Scientific

Biomarkers - blood

Lipoprotein(a) - blood

Hypolipidemic Agents - pharmacology

Practice Guidelines as Topic

Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease-related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

Metrics

20 Record Views

277 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.68 Lipids; 1.68.69 HDL
Web Of Science research areas: Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Creators: Don P Wilson - Department of Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, Fort Worth, TX, USA. Electronic address: don.wilson@cookchildrens.org
Terry A Jacobson - Department of Medicine, Lipid Clinic and Cardiovascular Risk Reduction Program, Emory University, Atlanta, GA, USA
Peter H Jones - Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Marlys L Koschinsky - Robarts Research Institute, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
Catherine J McNeal - Division of Cardiology, Department of Internal Medicine, Baylor Scott & White Health, Temple, TX, USA
Børge G Nordestgaard - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
Carl E Orringer - Division of Cardiology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
Publication Details: Journal of clinical lipidology, Vol.13(3), pp.374-392
Publisher: United States
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Cardiovascular
Language: English
Resource Type: Journal article
PMID: 31147269
Record Identifier: 991031576117002976